Research Topics
CAPMM Clinical Trials:
Scientists in the CAPMM have invented technology to make basic discoveries about disease mechanisms, to profile molecules relevant to individualized patient therapy, discover new chemoprevention strategies, and test these discoveries and hypothesis in clinical trials. The Center for Applied Proteomics and Molecular Medicine is working in collaboration with Inova Fairfax Hospital and the Side-Out Foundation to conduct clinical trials for breast cancer prevention and personalized breast cancer treatment. More clinical trials are being planned for other cancers.
The team also developed a nanoparticle technology, licensed to Ceres Nanosciences, which is being evaluated in a clinical trial at Inova Fairfax Hospital for early detection of Lyme disease.
Current Clinical Trials:
I SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Trail Recruitment & Information: http://clinicaltrials.gov/ct2/show/NCT01042379
Location:
Inova Health System, Fairfax, Virginia
Contact:
Alyssa Bruflodt, Phone: 703-776-3565, Email: Alyssa.Bruflodt@inova.org
Georgetown University Medical Center, District of Columbia
Minetta Liu, MD, 202-444-3677, Liumc@georgetown.edu
Additional nationwide locations listed at clinicaltrials.gov
Purpose:
The purposes of this study are: 1) to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors, 2) identify tissue and blood biomarkers that correlate and predict response to each therapy and 3) learn more about which early indicators of response are predictors of treatment success.
Sponsors and Collaborators:
Foundation for the National Institutes of Health
Side-Out Foundation
Clinical Trials.Gov Identifier: NCT01042379
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
(RECRUITMENT COMPLETED)
Trail Recruitment & Information: http://clinicaltrials.gov/ct2/show/NCT01023477?term=invasive+breast+neoplasia+AND+chloroquine+AND+PINC+AND+trial&rank=1
Locations:
-Virginia Cancer Specialists, PC, Fairfax, Virginia
-Medical Oncology and Hematology Associates of Northern Virginia, Fairfax,Virginia
-Virginia Surgery Associates, Fairfax, Virginia
-Inova Fairfax Hospital, Fairfax Virginia
Contact:
Heather Huryk, Phone: 703-776-4021, Email: Heather.Huryk@inova.org
Purpose:
The overall goal of this trial is to test a new therapy that has the potential to kill pre invasive early stage breast cancer before it can become invasive and life threatening. Our research (Espina et al) has identified a new therapeutic target, autophagy, that is used by the pre invasive cancer cells to survive inside the breast milk ducts. The autophagy pathway is inhibited by the oral medication chloroquine. The PINC trial will test the hypothesis that chloroquine will suppress or kill breast ductal carcinoma in situ (DCIS) cells, which are the precursor to invasive ductal breast carcinoma. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of the DCIS.
If you are a breast cancer patient and have a diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion you may be eligible to participate in the PINC trial. For additional eligibility criteria, visit the clinical trial.gov website and contact Heather Huryk (703-776-4021) for further details.
Sponsors and Collaborators:
Inova Health Care Services
George Mason University
Department of Defense
U.S. Army Medical Research Materiel Command
Clinical Trials.Gov Identifier: NCT01023477
Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer (Side-Out)
(RECRUITMENT COMPLETED)
Trail Recruitment & Information: http://clinicaltrials.gov/ct2/show/NCT01074814?term=Side-Out+metastatic++breast+cancer+clinical+trial&rank=1
Locations:
TGen Clinical Research Services Recruiting, Scottsdale, Arizona
Contact:
Joyce Schaffer, RN, MSN, OCN 480-323-1339 Email: joschaffer@shc.org
Gayle Jameson, MSN, ACNP-BC, AOCN 480-323-1350 Email: gjameson@shc.org
Fairfax North Virginia Hematology Oncology, Fairfax, Virginia
Stacey Banks, Phone: 703-208-3148 Email: stacey.banks@usoncology.com
Chloe Hamilton Email: chloe.hamilton@usoncology.com
Purpose:
The overall goal of this trial is to test a new therapy that has the potential to kill pre invasive early stage breast cancer before it can become invasive and life threatening. Our research (Espina et al) has identified a new therapeutic target, autophagy, that is used by the pre invasive cancer cells to survive inside the breast milk ducts. The autophagy pathway is inhibited by the oral medication chloroquine. The PINC trial will test the hypothesis that chloroquine will suppress or kill breast ductal carcinoma in situ (DCIS) cells, which are the precursor to invasive ductal breast carcinoma. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of the DCIS.
If you are a breast cancer patient and have a diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion you may be eligible to participate in the PINC trial. For additional eligibility criteria, visit the clinical trial.gov website and contact Heather Huryk (703-776-4021) for further details.
Sponsors and Collaborators:
TGen Drug Development Services
Side-Out Foundation
Clinical Trials.Gov Identifier: NCT01074814
*Clinicaltrial.gov identifier accessed from http://clinicaltrials.gov/ct2/home, provided by the U.S. National Library of Medicine*